JuvmoWhat to know
30-second read
For Neurology · Geriatric Medicine
- Who
- Adults with Parkinson’s disease — as monotherapy in early PD before starting levodopa, or added to levodopa in PD with motor fluctuations.
- What’s new
- Tavapadon (Juvmo), the first selective D1/D5 dopamine receptor partial agonist approved for PD; existing oral agonists (pramipexole, ropinirole, rotigotine) are D2/D3-selective.
- Evidence
- Three placebo-controlled Phase 3 TEMPO trials, 1,340 adults: significant motor gains in early PD (TEMPO-1, -2) and 1.1 more hours of good “on” time added to levodopa (TEMPO-3).
- Big advantage
- A new dopaminergic mechanism after decades of D2/D3-only agonists — an alternative when an existing agonist causes impulse-control symptoms or sedation.
- Key consideration
- Not tested head-to-head against other agonists or levodopa. Still carries dopamine-agonist risks (nausea, dizziness, dyskinesia, impulse-control); titration takes about 10 weeks.
- Availability
- Approved 28 September 2026; U.S. pharmacies expected October 2026. No list price yet; AbbVie has signaled it will miss 2027 Medicare Part D formulary cycles.
Practice impactConsider for selected patients
A genuine new mechanism, but tested only against placebo, not against the dopamine agonists and levodopa already in use. The clearest rationale today is a patient whose current agonist causes impulse-control symptoms or sedation.
The U.S. Food and Drug Administration approved Juvmo (tavapadon) on 28 September 2026 for adults with Parkinson’s disease, the first selective D1/D5 dopamine receptor partial agonist to reach the market — the first new dopaminergic mechanism approved for the disease in decades. AbbVie says it expects U.S. pharmacies to carry it in October 2026.
A receptor target no approved PD drug has used
Every oral dopamine agonist on the market — pramipexole, ropinirole, rotigotine — works by stimulating D2 and D3 dopamine receptors. Tavapadon instead is a partial agonist selective for D1 and D5 receptors, a different arm of the dopamine receptor family that earlier drug candidates struggled to target with oral bioavailability and a workable half-life. AbbVie acquired the molecule when it bought Cerevel Therapeutics, the Cambridge, Massachusetts biotech that originated it, for $8.7 billion in a deal announced in December 2023 and closed in August 2024.
The clinical rationale for D1/D5 selectivity is that D2/D3 signaling is more strongly implicated in two of dopamine agonists’ most troublesome effects: impulse-control disorders (compulsive gambling, shopping, eating or hypersexuality) and daytime somnolence, including sudden sleep onset. A D1/D5-selective drug is a reasonable hypothesis for a cleaner side-effect profile on those two axes specifically — but it is a mechanistic hypothesis, not a finding from tavapadon’s own trials, which were not designed or powered to prove it against an active comparator.
Cleared across the disease course, not for one stage
The approval covers two distinct uses. As monotherapy, it is indicated for adults with early Parkinson’s disease who have not yet started levodopa. As adjunctive therapy, it is indicated added to levodopa in patients with motor fluctuations — the “wearing-off” periods that emerge as PD progresses and levodopa’s effect becomes less consistent between doses. That breadth mirrors how existing dopamine agonists are used, and positions Juvmo as a substitutable option at either end of the disease course rather than a drug for one specific population.
What three placebo-controlled trials actually showed
The approval rests on the Phase 3 TEMPO program: three randomized, double-blind trials, all against placebo, totaling roughly 1,340 adults. None compared tavapadon against an existing dopamine agonist or against levodopa itself.
The TEMPO trials at a glance
MDS-UPDRS: Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, lower is better. TEMPO-1, -2 and -3 topline results as reported by AbbVie and independently covered by NeurologyLive, Practical Neurology and Drug Topics; TEMPO-3 published as Fernandez HH, Isaacson SH, Hauser RA, et al., JAMA Neurol. 2026;83(5):442-451.
The direction and statistical significance of every result is consistent across independent trade coverage of AbbVie’s own topline disclosures. What is missing from the public record is any comparison to an active treatment: a clinician cannot say from TEMPO alone whether tavapadon controls motor symptoms better, worse or about the same as the agonists and levodopa regimens already in routine use. The trials prove tavapadon beats placebo. They do not prove it beats anything a patient might currently be taking.
Juvmo among oral Parkinson's options
| Juvmo (tavapadon) | Pramipexole / ropinirole | Levodopa | |
|---|---|---|---|
| Receptor target | D1/D5-selective partial agonist | D2/D3-selective agonist | Dopamine precursor, converted centrally |
| Approved use | Monotherapy in early PD, or add-on to levodopa for motor fluctuations | Monotherapy in early PD, or add-on to levodopa | First-line for motor symptoms at any stage |
| Dosing | Once daily; 10-week titration pack to maintenance (5–15mg) | Once to three times daily depending on formulation | Multiple daily doses, often 3–5+ as disease progresses |
| Evidence base | 3 placebo-controlled trials, ~1,340 adults; no active comparator | Decades of placebo- and comparator-controlled trials and real-world use | Decades of use; the benchmark every other PD drug is measured against |
| Class safety concerns | Dopamine-agonist class effects reported in TEMPO (nausea, dizziness, dyskinesia, impulse-control); no boxed warning or REMS reported | Impulse-control disorders, sudden sleep onset, orthostatic hypotension | Dyskinesia and motor fluctuations with long-term use; no impulse-control signal |
Pramipexole/ropinirole and levodopa particulars from their own current labels, not from a head-to-head trial against tavapadon. Prescribe from the current labels, not this table.
The side-effect list is shorter on paper, not proven shorter in practice
In TEMPO-3, the add-on trial, the most common adverse events were nausea (14.3%), dyskinesia (10.0%) and dizziness (7.6%). These are the same categories of side effect associated with existing dopamine agonists — tavapadon has not eliminated them. No boxed warning or REMS program has been reported for Juvmo, consistent with other oral PD dopamine agonists, though Regulatory News was unable to independently retrieve the FDA-approved label this run to confirm that negative directly; prescribers should check the current label before relying on it.
The theoretical advantage — less impulse-control risk and less sedation from sparing D2/D3 stimulation — is the reason tavapadon exists, but it is a mechanistic argument, not a trial finding presented against an active comparator. Prescribers should counsel patients on impulse-control symptoms, sudden sleep onset and orthostatic hypotension exactly as they would for any dopamine agonist, and revisit that counseling as real-world and post-marketing data accumulate.
A ten-week climb to maintenance dose
- Five tablet strengths: a titration pack of 0.25mg and 1mg tablets, then 5mg, 10mg and 15mg maintenance tablets.
- Once daily, with or without levodopa.
- Gradual titration toward a 15mg/day target over roughly the first ten to fourteen weeks, with dose reductions (15mg→10mg or 10mg→5mg) available for tolerability.
- No published REMS requirement, consistent with other oral PD agonists, but confirm against the current label before prescribing.
Availability, and a Medicare timing problem AbbVie has already flagged
Juvmo is approved but not yet dispensed; AbbVie’s own timing is “October 2026,” and no list price has been disclosed. Reimbursement is uncertain beyond that. AbbVie’s chief commercial officer, Jeffrey Stewart, told a Morgan Stanley healthcare conference — as reported by financial-analysis outlet Tikr — that the company had missed the window for 2027 Medicare Part D formulary submissions and expects “a little bit of a slower burn” at launch. If that reporting holds, most Medicare Part D plans will not have a coverage decision on Juvmo until their 2028 formularies, meaning Medicare patients — the population most likely to have Parkinson’s disease — may face a year or more of out-of-pocket cost, prior authorization uncertainty or a wait before broad coverage is in place. Commercial payers will set their own timelines and step-therapy rules independently.
What changes in the clinic
- Patient selection. The clearest candidate is a patient on or considering a D2/D3 agonist who has, or is at risk for, impulse-control symptoms or problematic sedation — the one group for whom the mechanism offers a specific rationale beyond “another option.”
- Not a proven upgrade. There is no trial evidence that tavapadon controls motor symptoms better than an existing agonist or levodopa; do not switch a stable, well-controlled patient on that basis alone.
- Counseling stays the same. Impulse-control symptoms, sudden sleep onset and orthostatic hypotension still need to be screened for and discussed, exactly as with any dopamine agonist.
- Titration takes planning. A roughly ten-week climb to maintenance dose means this is not a same-visit prescribing decision for a patient who needs symptom control now.
- Coverage is not yet in place. Until a list price and payer decisions are public, this is a drug to discuss as an upcoming option, not one to promise a patient this month.
The honest summary is that Juvmo is a real mechanistic advance arriving with real evidentiary limits. It works, against placebo, at both ends of the Parkinson’s disease course. Whether it works better, or more safely, than what prescribers already reach for is a question TEMPO was not designed to answer, and one that coverage decisions will not resolve before 2027 at the earliest. Every story on this desk is filed by specialty on the For Physicians front.
How Juvmo got here, and what is next
- Dec 2023
AbbVie announces Cerevel acquisition
$8.7 billion deal brings tavapadon and Cerevel's neuroscience pipeline into AbbVie, closing August 2024.
- 2024
TEMPO-1, -2 and -3 report positive topline results
All three Phase 3 trials meet their primary endpoints against placebo.
- Sep 2025
NDA submitted
AbbVie files the New Drug Application for tavapadon with the FDA.
- 28 Sep 2026
FDA approves Juvmo
Cleared as monotherapy in early PD and as an add-on to levodopa for motor fluctuations.
- Oct 2026
Expected U.S. launch
AbbVie's own timing; list price not yet announced.
- 2028
Earliest likely broad Medicare Part D coverage
AbbVie has said it missed the 2027 formulary-submission window.
Sources & further reading
- ClinicalTrials.gov NCT04201093, “Efficacy and Safety of Tavapadon as Fixed-Dose Treatment in Early Parkinson's Disease (TEMPO-1).” clinicaltrials.gov
- ClinicalTrials.gov NCT04223193, “Flexible-Dose Trial in Early Parkinson's Disease (TEMPO-2).” clinicaltrials.gov
- ClinicalTrials.gov NCT04542499, “Study of Tavapadon as Adjunctive Therapy in Parkinson's Disease With Motor Fluctuations (TEMPO-3).” clinicaltrials.gov
- NeurologyLive, “FDA Approves Tavapadon for the Treatment of Parkinson Disease,” 28 September 2026. neurologylive.com
- Fierce Pharma, “AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease,” 28 September 2026. fiercepharma.com
- Pharmacy Times, “FDA Approves Tavapadon, First D1/D5 Agonist, for Parkinson Disease,” 28 September 2026. pharmacytimes.com
- Practical Neurology, “For People with Parkinson Disease, Tavapadon Adjunctive Therapy to Levodopa Increased Good ON Time” (TEMPO-3 topline), reporting on Fernandez HH, Isaacson SH, Hauser RA, et al., JAMA Neurology 2026;83(5):442-451. practicalneurology.com
- CNBC, “AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion,” 6 December 2023. cnbc.com
undefined
Frequently asked questions
Is tavapadon proven better than existing dopamine agonists or levodopa?
No head-to-head trial exists. All three TEMPO trials compared tavapadon against placebo, not against pramipexole, ropinirole, rotigotine or levodopa. It is a new mechanism with its own placebo-controlled evidence, not a demonstrated improvement over current options.
Does tavapadon still carry dopamine-agonist side effects like impulse-control disorders?
Yes. The D1/D5 mechanism is mechanistically distinct from D2/D3 agonists, which are more strongly linked to impulse-control symptoms, but tavapadon's own trials still reported nausea, dizziness, dyskinesia and impulse-control-type adverse events. No boxed warning or REMS program has been reported, but this is not a side-effect-free option.
When will Juvmo be available and what will it cost?
AbbVie expects U.S. pharmacies to have it in October 2026. No list price has been announced. AbbVie's own commercial leadership has said the company missed the window for 2027 Medicare Part D formulary cycles, meaning broad coverage is unlikely before 2028.
